Immutep Limited is a biotechnology enterprise focused on the exploration and advancement of medicinal candidates. The company specializes in creating immunotherapeutic solutions for treating both cancerous conditions and autoimmune disorders. Its primary investigational drug is eftilagimod alpha (referred to as efti or IMP321), a recombinant protein currently in a Phase IIb clinical trial, being assessed as a chemoimmunotherapy combination for metastatic breast cancer.